The off-label use of drugs in oncology: a position paper by the European Society for Medical Oncology (ESMO)
Open Access
- 1 December 2007
- journal article
- research article
- Published by Elsevier in Annals of Oncology
- Vol. 18 (12) , 1923-1925
- https://doi.org/10.1093/annonc/mdm517
Abstract
All drugs need to be given a marketing authorization by a relevant regulatory body in order for patients to receive them [1]. The marketing authorization is granted if the drug is judged to be safe and effective for a given indication following a given administration regimen. This is the drug ‘label’. When the drug is used for other indications, it is used ‘off label’.Keywords
This publication has 10 references indexed in Scilit:
- Promoting, improving and accelerating the drug development and approval processesDrug News & Perspectives, 2009
- European Perspective on the Costs and Cost-Effectiveness of Cancer TherapiesJournal of Clinical Oncology, 2007
- Reimbursement for Cancer Treatment: Coverage of Off-Label Drug IndicationsJournal of Clinical Oncology, 2006
- ASCO-ESMO consensus statement on quality cancer careAnnals of Oncology, 2006
- The advisory process for anticancer drug regulation: a global perspectiveAnnals of Oncology, 2005
- Off-label prescribing in oncologySupportive Care in Cancer, 2004
- Unlicensed and off label drug use in acute lymphoblastic leukaemia and other malignancies in childrenAnnals of Oncology, 2003
- Off label use—label off use?Annals of Oncology, 2003
- Reimbursement Policies Constrain the Practice of OncologyJAMA, 1991